Holen Sie sich die Stockscreener-App
1.43
0.70%
0.01
Vorhandelsmarkt:
1.43
Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten
Acurx Pharmaceuticals Inc (ACXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.430|Chg%:+0.010 - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.420|Chg%:-0.030 - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.435|Chg%:+0.015 - TradingKey
Acurx Pharmaceuticals (ACXP) Income Statement & Earnings - Moomoo
Acurx Pharmaceuticals (ACXP) Registration filing Summary - Quartr
Acurx Pharmaceuticals (ACXP) upgraded to buy: Here's why - MSN
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection - Yahoo Finance Singapore
Acurx data: beneficial gut bacteria remain after repeated C. diff. courses - Stock Titan
Price to earnings forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Acurx Pharmaceuticals Inc. (ACXP) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update - Yahoo Finance
Acurx to discuss Q2 results and business update Aug. 14 - Stock Titan
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference - AOL.com
Acurx Pharmaceuticals outlines its antibiotic pipeline as investors weigh long-term prospects - Ad-hoc-news.de
Acurx Pharmaceuticals (ACXP) Stock Analysis Report | Financials & Insights - Benzinga España
What date does Acurx Pharmaceuticals's (ACXP) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Clostridium Difficile Infections Market Forecast Signals - openPR.com
ACXP Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Gains on Operational Updates - dars.gov.et
Price to book forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Enterprise value to EBITDA forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Price to book forward of Acurx Pharmaceuticals, Inc. – MUN:3ZO0 - TradingView
Enterprise value to EBITDA forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Price to earnings forward of Acurx Pharmaceuticals, Inc. – MUN:3ZO0 - TradingView
Price to earnings forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Acurx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ACXP) - TradingView
ACXP Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Price to sales forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Enterprise value to revenue forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Acurx Pharmaceuticals (ACXP) Study update presentation Summary - Quartr
Enterprise value to EBIT forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Acurx Pharmaceuticals (ACXP) Holds Above Support After Modest GainParabolic SAR - DonanımHaber
Acurx Pharmaceuticals StockLong-term strategy and pipeline in focus - AD HOC NEWS
Acurx Pharmaceuticals Inc (ACXP) Institutional Confidence - TradingKey
Acurx presents research on ibezapolstat mechanism at Leiden conference - Investing.com UK
Inside Acurx’s 3.2Å look at a new antibiotic for drug‑resistant bacteria - Stock Titan
Certain Common Stock of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Warrants of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Stock Options of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
ACXP Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress ContinuesEarnings Forecast Report - newsline.com
Acurx Pharmaceuticals (ACXP) Stock Slides Slightly as Price Tests SupportMcClellan Oscillator - newsline.com
ACXP Q1 2026 Earnings: Narrower-than-Expected Loss Delivers Positive SurpriseEarnings Trend Analysis - newsline.com
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why - Yahoo Finance
Acurx Pharmaceuticals stock (US00366D1037): Nasdaq price steady as investors eye valuation metrics - AD HOC NEWS
Acurx Pharmaceuticals (ACXP) Slides 5.08% as Support Level NearsBuyback Factor - DonanımHaber
Acurx Pharmaceuticals (ACXP) Declines 6.74% as Stock Nears Key Support at $1.71Trend Following Picks - dars.gov.et
Acurx Pharmaceuticals stock (US00366D1037): Analyst consensus points to high upside from low Nasdaq - AD HOC NEWS
ACXPAcurx Pharmaceuticals Inc Latest SEC Filings - Finviz
ACXP Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Progress ContinuesDividend Growth Analysis - The Legal Advocate
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):